Skip to main content
. 2018 Mar 1;7(4):259–268. doi: 10.1002/psp4.12287

Table 2.

Population pharmacokinetic parameter estimates and bootstrap results for total testosterone in 31 healthy volunteers.

Parameter Final model Bootstrapa
Estimate Median RSE (%) 95% CI
CL/F, kL/day 2.6 2.6 4.53 (2.42–2.8)
V/F, kL 14.4 14.4 12.1 (11.9–17.6)
Ka, day1 1.22 1.22 44.9 (0.785–2.67)
βbase, mg/day 6.24 6.25 23.3 (3.53–8.09)
Lambda(λ)
1.18 1.43 55.9 (0.43–2.74)
Emax, mg/day 12.5 12.3 25.2 (7.75–18)
LH50, IU/L 12.9 12.7 63.1 (0.892–23.7)
A_0, TC 6.24 6.21 5.82 (5.63–6.85)
θBalbuminV 
−1.55 −1.84 58.7 (−3.56 to −0.842)
θCalbuminV 
−0.27 −0.27 25.4 (−0.369 to −0.108)
θBWTV 
1.71 1.77 36.7 (0.776–2.98)
θBWTCL 
0.785 0.793 17.4 (0.595–1.03)
θCWTCL 
0.016 0.016 45.2 (0.00382–0.0254)
σ2 additive
0.261 0.191 105 (0.00261–0.839)
σ2 proportional
0.057 0.057 18.7 (0.039–0.073)
IIV_CLb 9.66% (25.2) 8.60% 57.3 (2.98%–12.29%)
IIV_V 37% (14.6) 35.9% 52.8 (18.3%–51.7%)
IIV_Ka 53.9% (42.5) 52.4% 89.7 (0.54%–87.5%)
IIV_ Emax 45.3% (16.3) 43.1% 71.6 (14.5%–66.3%)
IIV_ λ 75.9% (25.3) 72.9% 47.4 (40.0%–99.6%)
IIV_A_0, TC 13.6% (49.6) 13.3% 77.1 (0.14%–21.3%)

CI, confidence interval; CL, clearance; E max, maximum effect; IIV, inter‐individual variability; RSE%, percentage of relative standard error; TC, testosterone cypionate; V, volume.

a

Median, RSE, and 95% CIs were calculated based on 500 nonparametric bootstrap results.

b

Shrinkage of IIV parameters was reported along with parameter estimates.